Arcutis Biotherapeutics, Inc. (ARQT)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-06

Key Insights

Arcutis filed an 8-K on May 6, 2026 to disclose Q1 2026 financial results, indicating the company is actively reporting earnings performance to shareholders and the market.
The filing is limited to Results of Operations and Financial Condition (Item 2.02) with the actual press release content referenced as Exhibit 99.1, suggesting this is a routine quarterly earnings announcement rather than a material corporate event.
The document is signed by Chief Financial Officer Latha Vairavan, confirming proper corporate authorization and financial disclosure procedures are being followed in accordance with SEC requirements.

Quarterly Report Filed: 2026-05-06

Key Insights

The filing is incomplete with truncated content, preventing full analysis of Q1 2026 financial performance, revenue trends from ZORYVE product lines, and cash runway metrics critical for a pre-commercial or early-stage biopharmaceutical company.
Multiple product variants tracked (ZORYVE Cream 0.05, 0.15, 0.3 and Foam) suggest commercial launch phase for dermatology franchise, but actual sales figures and market uptake data are not accessible in the provided excerpt.
Company maintains fair value investment portfolio (money market funds, CDs, Treasury securities, corporate debt) and has a secured debt facility, indicating active capital management and debt financing arrangements typical of cash-burning biotech firms.
Equity interests in Ducentis Biotherapeutics and ongoing partnerships with AstraZeneca, Huadong, and Sato suggest diversified pipeline and licensing strategy, though specifics on milestones, royalties, and financial contributions cannot be determined from truncated filing.

Insider Trading Filed: 2026-04-03

Key Insights

Insider Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) on April 1, 2026, reducing his direct ownership to 39,744 shares.
The sale was made pursuant to a 10b5-1 trading plan adopted on March 11, 2025, indicating a pre-planned transaction rather than an opportunistic sale.
The sale price of $23.88 per share was within a range of $23.61 to $24.12, suggesting the transaction was executed at market prices.

Insider Trading Filed: 2026-01-07

Key Insights

The reporting person, Patrick Burnett, an executive at Arcutis Biotherapeutics, Inc. (ARQT), sold 2,490 shares of the company's common stock on January 5, 2026, at a weighted average price of $28.9822 per share.
The sale was executed pursuant to a 10b5-1 trading plan that was adopted on December 12, 2024, indicating a pre-planned transaction.
After the reported transaction, the reporting person still holds 94,120 shares of the company's common stock, indicating they maintain a significant ownership position.

Insider Trading Filed: 2026-01-06

Key Insights

The reporting person, Howard G. Welgus, sold 10,000 shares of Arcutis Biotherapeutics, Inc. (ARQT) on January 2, 2026 at a weighted average price of $28.9606 per share.
The sale of shares was executed pursuant to a 10b5-1 trading plan adopted by the reporting person on March 11, 2025, with a plan end date of May 29, 2026.
Following the reported transaction, the reporting person still holds a direct ownership of 69,744 shares of the issuer's common stock.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.